Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
Open Access
- 13 November 2019
- journal article
- abstracts
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 245